The decline in immunisations against some diseases is the first in nearly 30 years, the UN says.
Category Archives: Longevity
Add More Constraints for Better Decisions
It’s tempting to try to keep your options open. People often assume that having more options is equivalent to having more freedom. But actually the opposite tends to be true when it comes to making aligned decisions. When you keep your options too open, you keep your standards too low.
When people have too many options to intelligently assess, they tend to settle for choices that are good enough but not great.
But when you narrow the range to a few options that you can reasonably consider one by one, you’re more likely to go for the best choice, at least among those options.
Consider buying a new piece of tech. If you’re only considering two or three models, it’s easier to identify the best one for your needs. But if you have hundreds or thousands of options available, picking the optimal one for you seems hopeless.
This is a common issue when it comes to finding an aligned career path or an aligned relationship. When you have too few constraints, you have too many options. This can make you feel doubtful or even paralyzed about making a decent decision.
It may seem counterintuitive to narrow your options by adding more constraints, but it works well in practice, especially when you choose constraints that elevate your standards.
When I’m ready to buy a new phone, laptop, tablet, or watch, for instance, I’m only going to consider Apple products. I’ve been using products in their ecosystem for many years, and I’m pleased with them. So when making such purchase decisions, I wouldn’t consider stepping outside the Apple space unless something goes really wrong. My last 4 phones, last 3 laptops, last 4 tablets, and last 3 watches were all iPhones, MacBook Pros, iPads, and Apple Watches, respectively.
This simple constraint creates a pathway to investing more deeply in a relationship with Apple too. I’m on a first-name basis with a member of the business team at the local Apple Store, and she regularly arranges discounts for me. So constraints can lead to more depth and efficiency for related future decisions.
What about finding an intimate relationship partner? First consider how to rule out partial matches and mismatches.
For me to be deeply involved with a woman, she must be a committed vegan. She has to be interested in open relationships. She has to be into D/s play. She must be into personal growth. By narrowing the vast field of possibilities down to a relatively small number of options, I can eliminate many risks related to partial matches, such as the risk of over-investing in a connection that isn’t going to work well.
If you want to date around a lot and aren’t feeling too particular, you can keep your options open, but you may find that approach dissatisfying or disappointing after a while. When you’d rather find a really strong match to invest in, add more constraints to narrow your options and raise your standards. It may surprise you how well this works, especially by helping you quickly decline partial matches.
Same goes for career options and income-generating opportunities. Start by eliminating options that aren’t fascinating, stimulating, and fun. Rule out whatever doesn’t feel purposeful and heart-aligned. Drop ideas that aren’t likely to be highly lucrative. Dump the possibilities that aren’t creative and growth-oriented. Keep narrowing your options till you start wondering if your standards might be too high.
In this particular area, I found it helpful to establish a minimum standard for considering business deals. For a while I didn’t consider any deal that would be worth less than $10K. Eventually I bumped that to $20K. Later I held it around $50K for a while. These days I tend not to bother considering business deals or projects unless they’re financially worth $100K or more. And on top of that, they still have to be fun, creative, stimulating, purposeful, etc.
Interestingly, this makes life easier and improves the odds of discovering really good options. It keeps me from getting bogged down in partial matches.
When thinking about relationship matches, consider the perspective of a really good match who’s looking for someone just like you. Does it make sense for them to remain receptive to less than what you can offer? I’d rather connect with a vegan who’s looking for a fellow vegan, not a vegan with lower standards. Would you rather be what someone is looking for… or what they’re settling for?
You may not be sure about how to identify or recognize an optimal solution, but what can you be pretty sure about? Start by adding some constraints where you are confident in your desires. Relationship-wise I can say it wouldn’t work out if I tried to get seriously involved with a non-vegan woman – our ethics and values wouldn’t align well enough. That by itself isn’t enough to guarantee a good match, but it’s an easy way to rule out a large swath of partial matches.
What are some equivalents for you? What constraints would help to steer you closer to a really strong match and away from partial matches?
If you do this right, you’re going to turn off partial matches. Some may feel a bit miffed that you’re excluding them without giving them a chance. But you’re also doing them a favor. You’re making it clear that you wouldn’t be a good investment in some dimension of life, so you’re saving them time, energy, and false hope. If you want to clarify your investment worthiness for an aligned option, you’d better be willing to disappoint partial matches up front. The smarter ones will actually respect you for this preventative no.
Aim for true success here. Don’t waffle on what you really want. Don’t pre-settle for less. Challenge your brain to figure out how to invite and experience what you really want. Start by ruling out whatever would feel a bit dissatisfying or disappointing – whatever feels like settling. What’s the relationship or career equivalent of a sad Android phone? 😉
Constraints are very freeing – they free you of the nasty traps of partial matches.
Health24.com | Moderna Covid-19 vaccine ‘promising’ after early trial
A leading Covid-19 vaccine contender has passed its early safety trial with flying colours.
The vaccine, created by Moderna, produced an immune response in all 45 healthy participants who received two shots 28 days apart, according to findings reported July 14 in the New England Journal of Medicine.
The vaccine (named mRNA-1273 for now) uses messenger RNA, or mRNA, to trigger an immune response to the Covid-19 coronavirus in patients.
Genetically derived from the virus, the mRNA vaccine essentially mimics a natural Covid-19 infection, tricking the body into producing antibodies that hopefully will protect against future infections.
More than half of the people given the vaccine developed some side effects, including fatigue, chills, headache and muscle pain. However, only people given the highest dose reported severe adverse effects, and no major safety concerns were identified.
“The results are promising but obviously need further confirmation and elaboration in later-stage clinical trials,” said Dr Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security in Baltimore.
“There is a lot of interest in the ability of mRNA vaccines to be the quickest route to a vaccine for emerging pathogens and hopefully this aspiration will be borne out with this vaccine.”
Moderna announced last week that it had completed enrollment for phase 2 clinical trials of mRNA-1273, including 300 healthy adults aged 18 to 55, along with 300 adults aged 56 and older.
This next phase is designed to tell doctors more about how well it works, as well as continuing to gather evidence on its safety. Participants will randomly receive either a low dose of the vaccine, a high dose or a placebo, and researchers will track the progress of all three groups.
The United States has agreed to provide up to $483m to Moderna as part of Operation Warp Speed, a federal effort to make coronavirus vaccines and treatments available to the American public as quickly as possible.
The US National Institutes of Health is funding the mRNA-1273 clinical trials
Image credit: Unsplash
Spread of flu virus in hospital environment common
One in four inpatients with influenza in a given season showed signs of having become infected during care. This is clear from a University of Gothenburg thesis about the spread of influenza in hospitals and how this problem can be remedied.
One of the studies in the thesis is based on a review of the medical records of all 435 hospitalized adult patients at Sahlgrenska University Hospital who had laboratory-confirmed influenza (flu) during the 2016-2017 season.
Of these patients, 114 cases (26 percent) were classified as healthcare-associated. These patients had been admitted for other reason, and the onset of their flu symptoms did not take place until 48 hours or more after admission.
A detailed genetic analysis of virus samples was also performed. This analysis showed a close genetic relationship between flu viruses in samples taken from patents staying in the same ward within a single week.
“Besides the association in time and space, a kind of DNA evidence, like from a crime scene, was used. Overall, teher’s strong support for transmission of infection within the hospital,” says Martina Sansone, PhD a recent PhD graduate at Sahlgrenska Academy, University of Gothenburg, and a consultant in infectious diseases and hospital hygiene at Sahlgrenska University Hospital.
“The proportion who became infected within the hospital was even higher than I thought it would be — and after all, this is my job,” she continues. “This research area isn’t especially well explored.”
Twenty-six people in the study group died. The majority were older patients with cardiac or pulmonary diseases, and the seasonal flu of 2016-2017 was considered relatively severe.
Based on her doctoral studies in their entirety — including a flu outbreak at Kungälv Hospital — Sansone concludes that transmission of influenza in hospital wards is common.
The shortage of beds is identified as a key factor in the context. The lack of single rooms also leads to more transfers of patients within a hospital and this, in turn, can add to the spread of infection.
“There has been an exaggerated focus on measurable lead times in the emergency room, and on cutting wait times. Sometimes the decision to hospitalize a patient is taken too quickly, before the diagnosis is complete and the risk of a person being infectious is known to exist. I also think the staff sometimes finds it hard to grasp the fact that one patient can represent a danger to another.”
The parallels with COVID-19 are obvious, Sansone thinks. Respiratory tract symptoms are common and may be mild. In the flu season too, planned care may be postponed and patients need to be kept isolated in the hospital environment.
“In Sweden our hospitals have been extremely open, to family members as well as others, with lots of people coming and going. Why not have separate flu wards, in the same way as we have COVID-19 wards?” she wonders.
“The crucial needs are for us to reduce numbers of contacts, carry out prompt flu testing in the emergency room, and increase the vaccination rates. Today, around 50 percent of the elderly population in Sweden are vaccinated against the seasonal flu, well below the WHO target of 75 percent,” Sansone says.
Title: Epidemiology of viral respiratory infections with focus on in-hospital influenza transmission; http://hdl.handle.net/2077/63619
Story Source:
Materials provided by University of Gothenburg. Original written by Margareta Gustafsson Kubista. Note: Content may be edited for style and length.
Boosting immune memory could reduce cancer recurrence
Blocking a newly identified “immune memory checkpoint” in immune cells could improve immunotherapy and help prevent cancers from recurring, according to new findings in mice and human samples by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. The research was published this week in Nature Immunology.
Immunotherapy drugs that harness the body’s own immune system to fight cancer have revolutionized the treatment of many cancers. They work by blocking checkpoint inhibitor proteins like PD1, removing the brakes from cancer-killing T cells in the immune system. However, only about a third of patients respond to these drugs.
“There is still much work to be done to improve cancer immunotherapy because only a small group of people benefit, and even among those, we see many tumors relapsing,” said Dario A.A. Vignali, Ph.D., who holds the Frank Dixon Chair in Cancer Immunology at Pitt’s School of Medicine and is the co-leader of the Cancer Immunology and Immunotherapy program at the UPMC Hillman Cancer Center. “Our findings point to an important new biological anti-tumor mechanism that we can exploit to provide durable, long-term immune response against tumors.”
Vignali and his colleagues discovered that a protein called Neuropilin-1 (NRP1) plays an important role in suppressing immune responses to cancer.
“We knew NRP1 was present on the surface of other T cells, but we wondered whether it somehow altered the function of the killer T cells,” said Chang “Gracie” Liu, Ph.D., a postdoctoral researcher in Vignali’s lab and first author of the publication. “We thought it might function like any other immune checkpoint molecule and that blocking it would prevent tumors from growing.”
Liu and her colleagues created a genetically modified mouse that had NRP1 removed specifically from the surface of only killer T cells. When they grafted tumor cells to this mouse model, they expected that the tumors would not grow or grow more slowly when compared to normal animals, as they had seen when blocking other checkpoint proteins. Instead, they saw no difference at all.
“We were a bit disappointed and thought we had hit a dead end because it looked like removing NRP1 did not impact anti-tumor immunity,” said Liu. “But instead of giving up, we asked a different question — does NRP1 change the capability of the immune system to remember the tumor?”
They removed the tumor, waited and grafted cancer cells again in a different location, mimicking how a tumor might come back in a patient who had surgery. They saw a dramatic effect. Mice that had NRP1 genetically deleted on killer T cells were better protected against the secondary tumor and responded more positively to anti-PD1 immunotherapy when compared to normal mice.
Further experiments revealed that neuropilin was controlling the fate of how T cells develop and establish immune memory. Having NRP1 caused the killer T cells to become exhausted and ineffective in fighting cancer cells, particularly long-term, while removing NRP1 resulted in T cells having an increased immune memory — the ability of the immune response to respond more potently when it “sees” a tumor again.
These findings in mice also correlated with studies of T cells isolated from the blood of patients with skin cancer or head and neck cancer. Patients with advanced stage head and neck cancer had higher levels of NRP1 on a subset of “memory” killer T cells and fewer of these cells compared to those with earlier stage disease. In patients with advanced skin cancer treated with various immunotherapies, higher NRP1 levels on killer T cells were associated with a poorer response to treatment and a smaller pool of memory T cells.
“This is a completely new area of understanding of how anti-tumor immunity is controlled and will present new therapeutic opportunities to promote and enhance a more durable, long-term anti-tumor response in cancer patients,” says Vignali.
Drugs that target NRP1 are already being tested in the clinic in combination with anti-PD1 immunotherapies, and these clinical trials will reveal much more about the role of immune memory in fighting cancer, says Vignali. “This is why persistence pays off. When our initial hypothesis turned out to be incorrect, we kept pursuing other possibilities and ended up with an important new discovery.”
Story Source:
Materials provided by University of Pittsburgh. Note: Content may be edited for style and length.
New study shows how plants regulate their growth-inhibiting hormones to survive
In a world with a consistently growing population and a climate crisis, food shortage is a looming threat. To alleviate this threat, crop scientists, botanists, genetic engineers, and others, have been exploring ways of boosting crop productivity and resilience. One way to control plant growth and physiology is to regulate the levels of “phytohormones” or plant hormones.
However, much remains to be known about the mechanisms that underlie this hormonal regulation in plants, limiting advancement in this direction. Now, in a study led by Nagoya University Japan, a team of scientists has discovered, using rice plants as the study model, that a process called “allosteric regulation” is involved in maintaining the phytohormonal balance in plants. Their findings, published in Nature Communications, could hold the key to significantly advancing the research on plant growth and development, providing a potential solution for food security.
Plants survive by adapting their development and physiology to their surrounding environments by controlling the levels of enzymes driving the synthesis of two phytohormones, gibberellin and auxin. Enzymes are proteins that bind to one or more reactant chemicals and speed up a reaction process. The binding site is called the activation site. In 1961, it was discovered that in bacteria, enzyme activity is enhanced or inhibited via allosteric regulation, which essentially is the binding of a molecule called the “effector” at a site other than the active site of the enzyme. In allosteric regulation, the structure of the enzyme changes to either support or hinder the reaction that the enzyme enables.
Professor Miyako Ueguchi-Tanaka of Nagoya University, lead scientist in the team that has now observed allosteric regulation in plants for the first time, explains their research findings, ”We used a technique called X-ray crystallography and found that, as molecules of the enzymes (gibberellin 2-oxidase 3 [GA2ox3], and auxin dioxygenase [DAO]) bind to gibberellin and auxin (respectively), they interact among themselves and form ‘multimeric’ structures, comprising four and two units respectively. As the amounts of gibberellin and auxin increase, so does the rate of multimerization of the enzymes. And multimerization enhances the activity of the enzymes, enabling greater degradation of gibberellin and auxin. Synchronous structural changes and activity enhancement are typical of allosteric-regulation events.”
The scientists further carried out “phylogenetic” analysis of GA2ox3 and DAO, which revealed that plants independently developed this hormone regulation mechanism at three separate time-points over the course of the evolutionary process.
Enthusiastic about the future prospects of these findings, Prof Ueguchi says, “The activity control system revealed here can be used to artificially regulate the activity of the growth inactivating hormones in plants. As a result, rice crop productivity can be improved and high-biomass plants can be produced in the event of food shortage or an environmental crisis.”
Of course, this study is only a stepping stone for now, and much remains to be done to see how the findings of this study can be applied practically in agricultural lands. However, these findings certainly are encouraging, and they signal the coming of a new era of sustainable development fueled by biotechnological advancements.
Story Source:
Materials provided by Nagoya University. Note: Content may be edited for style and length.
Blackburn facing ‘rising tide’ of coronavirus cases
A health boss says the majority of new cases in the area are in the south Asian community.
Health24.com | Streetlights could be harming your teen’s sleep and mental health
- Too much light at night can negatively affect teens’ sleep patterns and moods
- Artificial light is also associated with mood and anxiety disorders
- A good night’s rest is important as adolescents continue to face increasing levels of academic and performance stress
New research is suggesting links between street lights, neon signs, and other forms of nighttime outside lighting and sleeplessness, and mood disorders among teens.
The study of more than 10 000 American kids aged 13 to 18 couldn’t prove cause and effect. However, it found that teens living in areas with high levels of artificial outdoor light at night went to bed about 29 minutes later, on average, and got 11 fewer minutes of sleep, compared to teens in areas with the lowest levels of outdoor nighttime light.
What’s more, greater levels of artificial light were also associated with increased risk of a teen developing a mood or anxiety disorder.
Complex network of influences
Specifically, teens exposed to higher levels of artificial light at night were more likely to meet the diagnostic criteria for bipolar disorder or specific phobia, according to researchers led by Diana Paksarian, a postdoctoral research fellow at the US National Institute of Mental Health (NIMH).
“Environmental light exposure is only one factor in a more complex network of influences on sleep and behaviour,” stressed study co-author Kathleen Merikangas, senior investigator and chief of the Genetic Epidemiology Research Branch at the NIMH. But she believes it could be “an important target for prevention and interventions in adolescent health”.
As the researchers explained in an institute news release, sleep and circadian rhythm disruptions are features of certain mental disorders, including bipolar disorder. So, disrupted sleep might be the link connecting artificial nighttime light exposures and mental health disorders – something that should be examined in future studies.
The study also found social disparities in exposure to artificial light. Teens in racial/ethnic minority groups, from immigrant families, or from families with lower incomes were more likely to live in areas with high levels of outdoor light at night, the research showed.
A vital aspect of brain health
Two psychiatric experts who read over the new findings agreed that more research is needed.
While “it remains unclear what the mechanism of action may be,” the link between nighttime light and teen mental well-being “merits further investigation,” said Dr Victor Fornari, vice-chair of child and adolescent psychiatry at Zucker Hillside Hospital in Glen Oaks, New York. “Limiting artificial nighttime light may have a beneficial impact on mood,” he theorised.
Brittany LeMonda is senior neuropsychologist at Lenox Hill Hospital in New York City. She called the study “an interesting and timely article, as adolescents continue to face increasing levels of academic and performance stress”.
LeMonda said that “sleep is a vital aspect of brain health, physical health, cognitive health, and emotional, and is especially important during our formative adolescent years. We know that many adolescents do not get enough sleep, due to sleep latency, awakenings throughout the night, or early wake-up times.”
Simple interventions to reduce light
But there are easy solutions at hand, she added.
“The good news is that simple solutions – such as blackout curtains or using rooms not facing artificial light sources as bedrooms – could be positive and possibly simple interventions to reduce light, and hopefully improve sleep patterns and health outcomes,” LeMonda said.
The study was published online on 8 July in JAMA Psychiatry.
Image credit: iStock
NEXT ON HEALTH24X
Coronavirus: R number ‘lower than thought’ before lockdown eased in England
A study of 120,000 volunteers in England also suggests those aged 18 to 24 were more likely to test positive.
Health24.com | Upping fruit, veggies and grain intake can cut your diabetes risk by 25%
- New studies found that increasing fruit, vegetable and wholegrain consumption can prevent type 2 diabetes
- For example, people with the highest levels of wholegrain consumption had a 29% lower rate of type 2 diabetes
- This conclusion is only observational as studies can’t prove cause and effect
Eating more fruits, vegetables and wholegrain foods could lower your risk of type 2 diabetes, two new studies suggest.
In one study, researchers looked at more than 9 700 people who developed type 2 diabetes and over 13 600 who didn’t. Participants were from eight European countries and part of a long-term cancer and nutrition study.
After adjusting for lifestyle, and social and dietary risk factors for diabetes, people with the highest levels of fruit and vegetable consumption were 50% less likely to develop diabetes than those with the lowest levels, the researchers found.
High levels of wholegrain
Every 66 grams a day (2.3 ounces) increase in total fruit and vegetable intake was associated with a 25% lower risk of developing type 2 diabetes, Nita Forouhi, of the University of Cambridge in the United Kingdom, and colleagues calculated.
The other study included more than 158 000 US women and over 36 000 US men.
After adjusting for lifestyle and dietary risk factors for diabetes, people with the highest levels of wholegrain consumption had a 29% lower rate of type 2 diabetes than those with the lowest levels, the findings showed.
In terms of specific wholegrain foods, one or more servings a day of wholegrain cold breakfast cereal or dark bread was associated with a lower risk of type 2 diabetes (19% and 21%, respectively) compared with less than one serving a month.
Results back up recommendations
Two or more servings a week compared with less than one serving a month was associated with a 21% lower risk for oatmeal, a 15% lower risk for added bran, and a 12% lower risk for brown rice and wheat germ.
The reductions in diabetes risk appeared to plateau at around two servings a day for total wholegrain intake, and at around half a serving a day for whole grain cereal and dark bread, according to Qi Sun, an associate professor of nutrition at Harvard T.H. Chan School of Public Health in Boston, and colleagues.
The studies can’t prove cause and effect. Still, both research teams said their results back up recommendations to increase fruit, vegetable and wholegrain consumption as part of a healthy diet to prevent type 2 diabetes.
The studies were published on 8 July in the BMJ.
Image credit: iStock






